Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04736173 · ClinicalTrials.gov registry record · Phase 2
Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer
A Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Arcus Biosciences.
- Active
- Registry status
- Phase 2
- Development phase
- 169
- Enrollment target
- 20
- Study locations
NCT04736173: Active Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, sponsored by Arcus Biosciences.
NCT04736173 is a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer that is active but no longer recruiting, run by Arcus Biosciences. The registered enrollment target is 169 participants, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04736173, a Phase 2 study of Non-Small Cell Lung Cancer and Lung Cancer, is active but no longer recruiting, sponsored by Arcus Biosciences.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 169 participants
- Enrollment target
- 20
- Study locations
Study Summary
This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
Conditions Studied
Interventions
- DRUG Carboplatin
- DRUG Pemetrexed
- DRUG Paclitaxel
- DRUG Zimberelimab
- DRUG Domvanalimab
Study Locations (20)
Other
- Hong Kong United Oncology Centre - Hong Kong
- Humanity and Health Clinical Trial Centre - Hong Kong
- Hospital Sultan Ismail - Johor Bahru
- Hospital Kuala Lumpur - Kuala Lumpur
- Pantai Hospital Kuala Lumpur - Kuala Lumpur
- Universiti Kebangsaan Malaysia Medical Centre - Kuala Lumpur
- University Malaya Medical Centre - Kuala Lumpur
- Hospital Tengku Ampuan Afzan - Kuantan
- Hospital Umum Sarawak - Kuching
- Hospital Pulau Pinang - Pulau Pinang
- Institut Kanser Negara - Putrajaya
- Metro Davao Medical And Research Center Inc. - Davao City
- Philippine General Hospital - Manila
- St Luke's Medical Center - Manila
- Exellentis Clinical Trial Consultants - George
- Cancercare PE - Johannesburg
- University of Pretoria Medical Oncology - Pretoria
Georgia
- John B. Amos Cancer Center - Columbus
Texas
- Lumi Cancer Institute - Kingwood
Virginia
- Oncology and Hematology Associates of Southwest Virginia, Inc. - Blacksburg
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 169 participants |
| Start Date | 2021-02-08 |
| Est. Completion | 2027-05 |
| Phase | Phase 2 |
What the registry record for NCT04736173 still lists
NCT04736173 is an interventional study that assigns participants to a tested intervention. The registered 169 participants enrollment target is mid-sized for trials with a published cap, below the 652-participant average among 454 other Non-Small Cell Lung Cancer trials with a reported enrollment target (74% lower).
The record links to 4 conditions, with Non-Small Cell Lung Cancer appearing as the primary indexed condition, and to 5 interventions - of which Carboplatin is the first listed.
NCT04736173 names 20 study sites across 4 states, led by Other, Georgia, Texas.
Frequently Asked Questions
What is clinical trial NCT04736173 about?
NCT04736173 is a clinical study titled "Study Evaluating Effectiveness and Safety of Zimberelimab and Domvanalimab in Lung Cancer". This is a phase 2 study to evaluate zimberelimab (AB122) combined with domvanalimab (AB154) in front-line, PD-L1-high, locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC).
What is the current status of trial NCT04736173?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 169 participants. The study started on 2021-02-08. Estimated completion is 2027-05.
What conditions does trial NCT04736173 study?
This clinical trial studies the following conditions: Non-Small Cell Lung Cancer, Lung Cancer, Non-squamous Non-small Cell Lung Cancer, Squamous Non-Small Cell Lung Cancer.
What interventions are being tested in trial NCT04736173?
The interventions under investigation include: Carboplatin (DRUG), Pemetrexed (DRUG), Paclitaxel (DRUG), Zimberelimab (DRUG), Domvanalimab (DRUG).
Who is sponsoring clinical trial NCT04736173?
This trial is sponsored by Arcus Biosciences, which has 25 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04736173 being conducted?
This trial has 20 study locations across Georgia, Texas, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Non-Small Cell Lung Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04736173's enrollment target sits among peer trials
169 184th of 454 higher than 271 of 454 other Non-Small Cell Lung Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Non-Small Cell Lung Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Neoantigens in People With Metastatic Cancer
RECRUITING · Phase 2
-
Reduced CT + Anti-PD-1 as First Line Tx in Vulnerable Older Adults w/Adv <50% PD-L1 Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-Pemetrexed for EGFR-mutated Non-small Cell Lung Cancer After Failure of EGFR TKI Therapy (IZABRIGHT-Lung01)
RECRUITING · Phase 2
-
A Study to Evaluate Two Dosing Regimens of Subcutaneous Nivolumab in Combination With Intravenous Ipilimumab and Chemotherapy in Participants With Previously Untreated Metastatic or Recurrent Non-Small Cell Lung Cancer (NSCLC)
RECRUITING · Phase 2
-
Zelenectide Pevedotin in NECTIN4 Amplified Advanced or Metastatic Non-small Cell Lung Cancer
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06191484 · 169 participants · NA
Risk and Resilience to Suicide Following Late-Life Spousal Bereavement
- NCT02016430 · 170 participants · NA
Gut Flora Metabolite Reduction After Dietary Intervention (GRADY)
- NCT02621021 · 170 participants · Phase 2
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of Pembrolizumab
- NCT04094701 · 170 participants · NA
Hip Arthroscopy Postoperative Opioid Demands
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI